Patient safety remains a cornerstone of the global medical device industry, and the European Union is taking significant steps to uphold this principle. With the introduction of Article 10a under the Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR), manufacturers must proactively address potential supply interruptions that could jeopardize patient care.

Effective January 10, 2025, this regulation underscores the importance of advanced communication, ensuring stakeholders are adequately informed about anticipated disruptions. Let’s explore the key aspects of Article 10a, why early compliance matters, and how manufacturers can prepare.

What Is Article 10a and Why Does It Matter?

Article 10a introduces stringent obligations for manufacturers to minimize risks associated with supply interruptions of medical devices and in vitro diagnostic devices. By mandating early notifications, the regulation empowers stakeholders—healthcare providers and regulators—to take timely mitigating actions. This proactive approach reflects the EU’s commitment to protecting public health and enhancing supply chain transparency.

Key Requirements and Timelines

Advance Notification

• Minimum Six Months’ Notice: Manufacturers must notify relevant stakeholders of planned supply interruptions or discontinuations at least six months in advance.
• Exceptions: In exceptional cases where six months’ notice isn’t feasible, manufacturers must notify without delay to enable timely stakeholder action.

Notification Recipients

1. Competent Authorities: Regulatory bodies in the Member State where the manufacturer or authorized representative is located must be informed.
2. Supply Chain Partners: Notifications must reach downstream stakeholders, including economic operators, health institutions, and healthcare professionals.
3. Relay Obligations: Economic operators receiving these notifications must ensure the information is passed along to relevant stakeholders.

Why Early Compliance Matters

Although Article 10a will be enforced starting in 2025, adopting it early demonstrates a commitment to patient safety and regulatory excellence. Early compliance offers several advantages:

• Enhanced Trust: Build stronger relationships with regulators and stakeholders.
• Streamlined Operations: Early preparation minimizes disruptions and aligns supply chain partners.
• Regulatory Alignment: The EU’s standardized notification form simplifies compliance and reporting processes.

Proactive Steps for Manufacturers

1. Establish Clear Notification Processes

Develop internal protocols to identify and report potential supply disruptions or discontinuations promptly.

2. Engage Stakeholders Early

Build communication channels with stakeholders and encourage feedback to refine your notification practices.

3. Conduct Trial Runs

Simulate the notification process to identify potential bottlenecks and refine your strategy.

4. Monitor Supply Chain Risks

Implement robust systems to detect early disruptions and conduct regular risk assessments.

5. Collaborate with Economic Operators

Align with distributors and suppliers to clarify notification and relay responsibilities.

6. Document and Report

Maintain detailed records of notifications and related actions to ensure compliance and transparency.

Arazy Group: Your Partner in Compliance

With 30 years of global regulatory expertise, Arazy Group is your trusted partner for navigating MDR/IVDR requirements. Our comprehensive solutions simplify compliance, helping you stay ahead of regulatory changes while prioritizing patient safety.

Contact us today to learn how we can support your journey to Article 10a compliance.